The portfolio maintains a cost advantage over competitors, priced within the least expensive fee quintile among peers.
iShares Genomics Immnlgy & Hlthcr ETF IDNA
Morningstar’s Analysis IDNA
Will IDNA outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 42.8
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Sarepta Therapeutics Inc | 4.64 | 6.6 Mil | Healthcare |
Gilead Sciences Inc | 4.59 | 6.5 Mil | Healthcare |
Roche Holding AG | 4.52 | 6.4 Mil | Healthcare |
Incyte Corp | 4.50 | 6.4 Mil | Healthcare |
Revolution Medicines Inc Ordinary Shares | 4.38 | 6.2 Mil | Healthcare |
Sanofi SA | 4.17 | 5.9 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 4.12 | 5.9 Mil | Healthcare |
Exelixis Inc | 4.07 | 5.8 Mil | Healthcare |
Takeda Pharmaceutical Co Ltd | 3.96 | 5.6 Mil | Healthcare |
BeiGene Ltd Ordinary Shares | 3.90 | 5.5 Mil | Healthcare |